✦ LIBER ✦

Is it possible to discontinue imatinib mesylate therapy in Chronic Myeloid Leukemia patients with undetectable BCR/ABL? A case report and a review of the literature

✍ Scribed by Salvatore Guastafierro; Umberto Falcone; Maria Celentano; Milena Coppola; Maria Giovanna Ferrara; Antonello Sica

Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 111 KB
Volume: 33
Category: Article
ISSN: 0145-2126
DOI: 10.1016/j.leukres.2008.11.027

No coin nor oath required. For personal study only.

✦ Synopsis

Imatinib mesylate (IM) therapy leads to a complete cytogenetic response (CCyR) in 75-90% of Chronic Myeloid Leukemia (CML) patients in chronic phase, but only a small percentage of patients achieve complete molecular response (CMR). Very little is known about IM discontinuation. We report the case of a 20-years-old male patient in chronic phase CML who maintained undetectable BCR/ABL mRNA levels, despite IM discontinuation over a period of 15 months after achieving CMR. Our patient reached CCyR and CMR after 3 and 6 months of IM treatment, respectively. We also reviewed the published literature concerning cases of IM discontinuation.

📜 SIMILAR VOLUMES

Occurrence of colon adenocarcinoma in ch

Occurrence of colon adenocarcinoma in chronic myeloid leukemia patients treated with imatinib: Report of two cases and review of the literature

✍ A. Frustaci; M. Breccia; L. Cannella; C. Stefanizzi; G. Alimena 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 74 KB

Pilot study of lonafarnib, a farnesyl tr

Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy

✍ Gautam Borthakur; Hagop Kantarjian; George Daley; Moshe Talpaz; Susan O'Brien; G 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 105 KB 👁 2 views

Complete hematologic and cytogenetic res

Complete hematologic and cytogenetic response to 2-amino-9-β-D-arabinosyl-6-methoxy-9H-guanine in a patient with chronic myelogeneous leukemia in T-cell blastic phase : A case report and review of the literature

✍ Alvaro Aguayo; Jorge E. Cortes; Hagop M. Kantarjian; Miloslav Beran; Varsha Gand 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 97 KB 👁 1 views

## BACKGROUND. T-cell lymphoid blastic phase (BP) transformation is rare in chronic myelogenous leukemia (CML). 2-amino-9-␤-D-arabinosyl-6-methoxy-9H-guanine (GW506U78), a prodrug of arabinosylguanine (ara-G), is effective in T-cell leukemias. ## METHODS. The authors present a case of a 48-year